Keytruda
During a Q1 earnings call, Merck CEO Rob Davis discussed pipeline diversification plans and effects of tariffs on its manufacturing.
CureVac to Initiate Phase I Trial of mRNA Immunotherapy in NSCLC
The firm will evaluate CVHNLC in combination with Keytruda as a first-line and first-line maintenance treatment in NSCLC.
AstraZeneca, Daiichi Sankyo Begin First-Line Trial of Enhertu, Keytruda Combo in Gastric Cancer
The trial will include patients with locally advanced or metastatic HER2-positive, PD-L1-positive gastric or gastroesophageal junction cancer.
BMS is already testing the combo against just Keytruda as a first-line treatment in a Phase III trial in KRAS G12C-mutant and PD-L1-high tumors.
Bicara Therapeutics Begins Trial of Ficerafusp Alfa, Keytruda in First-Line Head and Neck Cancer
The Phase II/III trial will include patients with PD-L1-positive tumors and who are HPV-negative.